Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Für Investoren, die sich fragen, ob Merck mit einem aktuellen Preis von etwa US$120,76 noch Wert bietet oder ob der größte Teil des Aufwärtspotenzials bereits im Preis enthalten ist, wird in diesem Artikel die wichtigsten Überprüfungen erläutert, auf die sich Investoren verlassen. Mit einer Rendite von 0,4% über 7 Tagen, 7,5% über 30 Tagen, 13,4% bis zum Jahresende und 53,0% im Laufe des letzten Jahres haben viele Inhaber nun gefragt, ob der aktuelle Preis den Wert des Unternehmens genau widerspiegelt. Immer wieder werden in den jüngsten Schlagzeilen Mercks als eines der größten Pharmakonzerns erwähnt, seine laufenden Produktpipeline und die breitere Branchenstimmung. Diese Faktoren können alle das Risiko und das Potenzial beeinflussen, wie viel Prämie oder Diskont der Markt bereit ist, auf die Aktien zu legen. Auf Simply Wall Sts Bewertungsprüfungen hat Merck derzeit einen Wertescore von 3 von 6. In diesem Artikel werden verschiedene Bewertungsmethoden verglichen und abschließend wird eine umfassendere Art vorgestellt, wie man den Wert der Aktie denken könnte.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

KEYTRUDA (pembrolizumab) ist ein Immuntherapeutikum, das zur Behandlung verschiedener Arten von Krebs eingesetzt wird. Die folgenden Daten beschreiben die Efficacy und Sicherheit von KEYTRUDA in verschiedenen Krebsarten: Melanom, Non-Small-Cell-Lungenkrebs (NSCLC), Hals-Nasen-Ohren-Krebs (HNSCC) und Urotheliumskarzinom. Die Daten zeigen, dass KEYTRUDA in vielen Fällen eine gute Efficacy zeigt und bei einigen Patienten auch eine verbesserte Überlebensrate erreichen kann. Allerdings treten auch einige Nebenwirkungen auf, wie z.B. Pneumonie, Pneumonitis und Hautreaktionen. Es ist wichtig zu beachten, dass die Ergebnisse je nach Krebsart und individuellen Patientenbedingungen variieren können.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Bristol Myers Squibb BMY navigiert einen Umsatzmixwechsel, da das Wachstumsprodukteportfolio eine größere Rolle in der Geschäftsentwicklung einnimmt und den Einfluss der sinkenden Verkäufe von reifen Produkten gegenüber Generika mildert. Der Wachstumsbereich – einschließlich Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Camzyos, Breyanzi, Opdualag, Zeposia, Sotyku, Krazati und Cobenfy – wird zum zentralen Faktor für die Top-Linienresilienz. Die Verkäufe aus diesem Segment stiegen um 12 % im ersten Quartal 2026 und trugen damit 54 % der Gesamtumsätze bei, gegenüber 49,7 % im ersten Quartal 2025. Dieser Wechsel signalisiert eine verbesserte Umsatzdauer und unterstützt ein günstigeres Langfristwachstum.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?

Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Merck (MRK).

Merck currently has an average brokerage recommendation (ABR) of 1.73, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 30 brokerage firms. An ABR of 1.73 approximates between Strong Buy and Buy.

Of the 30 recommendations that derive the current ABR, 18 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 60% and 6.7% of all recommendations.

Brokerage Recommendation Trends for MRKBroker Rating Breakdown Chart for MRK

Check price target & stock forecast for Merck here>>>

The ABR suggests buying Merck, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.

Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.

This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.

Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.

Zacks Rank Should Not Be Confused With ABR

Although both Zacks Rank and ABR are displayed in a range of 1--5, they are different measures altogether.

The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.

Story Continues

It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.

In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.

In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.

Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.

Is MRK Worth Investing In?

In terms of earnings estimate revisions for Merck, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $5.17.

Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term.

The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Merck. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for Merck.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Merck & Co., Inc. (MRK) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Phibro Animal Health Corporation PAHC is drawing investor attention because its growth story is increasingly tied to Animal Health, the company’s largest and most strategically important business. The segment now anchors the revenue base, while vaccines, medicated feed additives (MFA) and nutritional specialties give Phibro multiple avenues for expansion.

The stock’s near-term setup depends on whether this segment can keep offsetting risks from regulation, currency swings and uneven demand in smaller businesses.

Here’s a look at Phibro’s stock performance over the past 12 months.Zacks Investment Research

Image Source: Zacks Investment Research

PAHC’s Growth Engine Inside Animal Health

Animal Health accounted for 74% of Phibro’s total revenues in fiscal 2025, making it the company’s clear growth engine. The segment grew 36% from fiscal 2024, reflecting the strength of a broader product platform across MFAs, nutritional specialty products and vaccines. The company develops, manufactures and markets more than 550 product presentations in this business, giving it a wide base of customers and species exposure.

For investors, the focus is simple. If Animal Health continues to grow, it can help Phibro absorb volatility in Mineral Nutrition and Performance Products while supporting a higher-quality earnings base.

Phibro’s MFA Franchise Gets a Bigger Runway

Phibro’s MFA franchise remains central to the Animal Health story, with its leading Stafac/V-Max/Eskalin platform is approved in more than 30 countries. The integration of Zoetis Inc.’s ZTS MFA business has brought more than 37 established product lines marketed across approximately 80 countries, along with six manufacturing sites in the United States, Italy and China.

That broader footprint expands Phibro’s ability to serve customers across regions and supports a larger recurring revenue base. This added scale is important because it does not rely on a single product or geography.

PAHC’s Q3 Segment Mix Shows the Momentum

The fiscal third-quarter 2026 results showed how that platform is translating into revenue momentum. Animal Health net sales increased 13% year over year to $291.2 million, ahead of the internal model projection of $265.7 million.

The acquired MFA business generated a full quarter of revenues and grew 25% over the prior-year period. Legacy MFA sales increased 5%, helped by demand in North America and certain antimicrobials sold by the Ethanol Performance business. Nutritional specialty product sales rose 8% on higher North America demand and higher companion animal sales.

Vaccines net sales were up 16% year over year. That segment mix supported management’s updated fiscal 2026 outlook, including net sales of $1.46 billion to $1.50 billion and adjusted EBITDA of $247 million to $255 million.

Story Continues

Phibro’s Vaccines Add a Differentiated Growth Vector

Phibro’s vaccine business gives Animal Health a growth avenue that differs from mature feed additive categories. In fiscal third-quarter 2026, vaccine sales rose 16%, driven by higher international demand, including Israel, along with stronger domestic swine demand and increased sales of autogenous vaccines.

The business includes approximately 50 product lines for poultry disease prevention, covering areas such as Infectious Bursal Disease, Infectious Bronchitis, Newcastle Disease, Reovirus, Salmonella and Coryza. As disease pressures shift, vaccines can become a more differentiated part of the portfolio because they are less exposed to generic competition than some feed additive categories.

Phibro is also investing in vaccine manufacturing capacity, including its production facility in Guarulhos, Brazil. That capacity expansion supports volume growth and broader access across geographies.

PAHC’s Global Footprint Helps Smooth Species Cycles

Phibro’s international reach adds another layer to the Animal Health case. The company markets nearly 770 product lines in more than 80 countries to about 4,000 customers, with operations focused on regions where livestock production is concentrated in large commercial farms.

That strategy supports product adoption and recurring demand. In fiscal third-quarter 2026, net sales rose 14% year over year in Europe, the Middle East and Africa, 9% in Asia Pacific, and 7% in Latin America and Canada.

Take a look at Phibro’s valuation.Zacks Investment Research

Image Source: Zacks Investment Research

Large peers such as Zoetis and Merck & Co., Inc. MRK also show how broad animal health platforms can benefit from scale, product depth and geographic reach, though Phibro’s mix remains more concentrated around its own feed additive, vaccine and nutrition strengths.

Phibro’s Outlook Balances Tailwinds With Known Risks

Phibro’s Health growth is being supported by the Zoetis MFA portfolio, steady legacy demand and higher vaccine volumes. Management also raised the low end of full-year expectations, a sign that recent execution has improved visibility. Yet, Brazil’s antimicrobial transition creates uncertainty for virginiamycin and bacitracin, while Mecadox remains under regulatory and legal scrutiny. Foreign exchange can also add earnings volatility, with fiscal third-quarter results including $1.9 million of foreign currency losses. Competition is another factor.

PAHC carries a Zacks Rank #2 (Buy), but the path is likely to remain uneven if Brazil disruption, currency pressure or generic competition weigh on the Animal Health growth engine.

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Merck & Co., Inc. (MRK) : Free Stock Analysis Report

Zoetis Inc. (ZTS) : Free Stock Analysis Report

Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.

Merck Animal Health has agreed to acquire TARGAN, a biodevice company focused on poultry solutions. The deal adds automated, technology driven tools aimed at the poultry sector to Merck's animal health offering. This marks a further step for Merck into animal health technologies alongside its human medicines business.

Merck (NYSE:MRK) is drawing fresh attention after its animal health unit moved to acquire TARGAN, a poultry focused biodevice developer. With the share price at $120.76 and a value score of 3, investors may view this as additional context when considering Merck, including its recent 13.4% year to date return and 53.0% return over the past year.

For shareholders, the TARGAN deal indicates an effort to build more depth in animal health and agriculture technology, areas that operate alongside Merck's established human pharmaceuticals business. Future updates on how TARGAN's technologies are integrated and commercialized within Merck Animal Health will help clarify what this development could mean for Merck's broader portfolio and competitive position in animal health solutions.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.NYSE:MRK Earnings & Revenue Growth as at Jun 2026

📰 Beyond the headline: 4 risks and 2 things going right for Merck that every investor should see.

Quick Assessment

⚖️ Price vs Analyst Target: At US$120.76 versus a consensus target of US$129.74, the stock sits about 7% below analyst expectations, which is inside the 10% buffer zone. ✅ Simply Wall St Valuation: Shares are flagged as trading about 47.2% below an estimated fair value, so this news lands while the stock screens as undervalued. ✅ Recent Momentum: A 30 day return of 7.5% shows the market has been pricing in more optimism recently.

There's only one way to know the right time to buy, sell or hold Merck. Head to Simply Wall St's company report for the latest analysis of Merck's Fair Value.

Key Considerations

📊 The TARGAN acquisition expands Merck Animal Health into poultry biodevices, which could make the animal health segment a more meaningful part of the overall story. 📊 Watch for updates on deal closing, integration costs, and any disclosures on revenue contribution from TARGAN over time. ⚠️ Merck already carries a high level of debt and has profit margins of 13.6% versus 27.3% last year, so investors may want to see that any extra spending linked to this deal is carefully managed.

Story Continues

Dig Deeper

For the full picture including more risks and rewards, check out the complete Merck analysis. Alternatively, you can check out the community page for Merck to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include MRK.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Gilead Sciences Inc. (NASDAQ:GILD) is one of the top large cap value stocks to buy now. On June 8, Gilead Sciences and Merck announced positive topline results from two Phase 3 clinical trials, ISLEND-1 and ISLEND-2, evaluating their investigational once-weekly oral HIV treatment. The regimen, which combines islatravir and lenacapavir, successfully met its primary efficacy endpoint at Week 48 in both studies, showing statistical non-inferiority when compared to daily standard-of-care antiretroviral therapies.

This novel combination uses two distinct mechanisms of action: islatravir, a next-generation nucleoside analog, and lenacapavir, a first-in-class capsid inhibitor that disrupts the HIV lifecycle at multiple stages. The companies reported that the safety profile of the once-weekly tablet was generally comparable to existing treatments, with no new safety concerns identified throughout the trials.Is Gilead (GILD) One of the Top Large Cap Value Stocks to Buy Now?

If approved, the regimen would become the first long-acting oral HIV treatment taken only once per week, offering patients increased flexibility and discretion. Gilead Sciences Inc. (NASDAQ:GILD) and Merck plan to submit these Phase 3 findings to global regulatory authorities and present detailed data at an upcoming scientific congress to further support the development of this potential new standard of care.

Gilead Sciences Inc. (NASDAQ:GILD) is a drug manufacturer that develops medicines for unmet medical needs. The company provides treatments for HIV-1, chronic hepatitis C, primary biliary cholangitis, chronic hepatitis B, and serious invasive fungal infections. It also offers T-cell and CAR T-cell therapies for adult patients, intravenous injections, and treatments for COVID-19.

While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Mergers and acquisitions (M&A) activity across pharmaceutical and biotech sectors has accelerated significantly in 2026, extending the strong recovery that began in 2025.

A recent surge in dealmaking underscores the industry's focus on portfolio expansion and continuous pipeline innovation, alongside a growing emphasis on AI-driven drug discovery. Oncology and immuno-oncology companies have always been at the top of acquisition targets. Major players are actively pursuing licensing agreements and collaborations around promising drugs and candidates to further strengthen and diversify their core portfolios.

Quick Take on Recent M&A Deals

Pharma conglomerate Johnson & Johnson recently announced that it will acquire Firefly Bio for $1 billion and gain access to its Firelink degrader antibody conjugate platform. The deal strengthens Johnson & Johnson's oncology pipeline by adding a targeted approach for KRAS-driven cancers, supporting its efforts to develop treatments for some of the most common and challenging solid tumors.

Other pharma giants Eli Lilly LLY and Novartis NVS have been on an acquisition spree this year.

Lilly recently announced agreements to acquire Curevo, LimmaTech Biologics, and Vaccine Company, expanding its infectious disease research and development capabilities.

Lilly has been actively expanding its pipeline through acquisitions. LLY is all set to acquire Ajax Therapeutics, which will add AJ1-11095, a potential first-in-class oral type II JAK2 inhibitor currently in phase I testing for myelofibrosis patients previously treated with type I JAK2 inhibitors, to its pipeline.  The company also announced a deal to acquire clinical-stage biotechnology company Kelonia Therapeutics, Inc, a pioneer in vivo gene delivery.

The company had earlier agreed to acquire Centessa Pharmaceuticals for up to $7.8 billion, which will add orexin-based sleep disorder candidate cleminorexton to its pipeline. Lilly also struck a deal worth up to $2.4 billion for Orna Therapeutics, to gain access to its circular RNA-based immune cell engineering platform. Lilly also acquired Ventyx Biosciences to strengthen its portfolio of oral therapies targeting inflammatory diseases.

Swiss pharma bigwig Novartis, too, has been very active on the M&A front.  NVS is set to acquire Excellergy Inc., strengthening its immunology pipeline with a focus on food allergies and other IgE-mediated conditions. The deal brings in EXL-111, a phase I, half-life-extended anti-IgE antibody.

Earlier this year, Novartis acquired Avidity Biosciences, adding its antibody oligonucleotide conjugate (AOC) platform and three late-stage programs, further bolstering its neuromuscular pipeline.

Story Continues

Last month, Merck MRK acquired Terns Pharmaceuticals for $53 per share in cash. The deal adds TERN-701, a potential best-in-class treatment for chronic myeloid leukemia that recently received FDA Breakthrough Therapy Designation. The acquisition strengthens Merck's oncology pipeline.

Among biotech giants, Gilead Sciences, Inc. GILD is ramping up its external innovation strategy through targeted acquisitions to strengthen its pipeline and reduce reliance on its core HIV franchise.

Gilead and partner Lakefront Biotherapeutics (formerly known as Galapagos) recently acquired Ouro Medicines, adding gamgertamig, a clinical-stage BCMAxCD3 T-cell engager, to strengthen their autoimmune disease and inflammation pipeline.

Last month, Gilead acquired Tubulis, a clinical-stage biotech focused on developing next-generation antibody-drug conjugates (ADCs), strengthening its oncology pipeline.

Earlier this year, GILD acquired Arcellx for about $7.8 billion. The acquisition gives Gilead full ownership of anito-cel, an investigational late-stage CAR-T therapy for multiple myeloma with a potential U.S. decision by December 2026.

Another biotech giant Biogen recently acquired Apellis Pharmaceuticals $41 per share in cash plus contingent value rights worth up to an additional $4 per share tied to future sales milestones. The acquisition adds two commercialized therapies, Empaveli and Syfovre, to Biogen's portfolio. Together, the drugs generated $689 million in sales in 2025. The transaction strengthens Biogen's presence in immunology and rare diseases while establishing a foothold in nephrology.

Earlier this week, GSK plc GSK announced that it will acquire clinical-stage biopharmaceutical company Nuvalent for $10.6 billion, gaining three lung cancer assets, including late-stage ROS1 inhibitor zidesamtinib and ALK inhibitor neladalkib, both under FDA review. The deal strengthens GSK's oncology pipeline, expands its presence in lung cancer, and is expected to contribute to sales and operating profit growth beginning in 2027.

GSK earlier acquired RAPT Therapeutics to strengthen its immunology pipeline. The company also bought 35Pharma, adding HS235, a potential best-in-class therapy for pulmonary hypertension.

Last week, Servier (an independent international pharmaceutical group governed by a foundation) agreed to acquire the muscular dystrophy business of Edgewise Therapeutics in a deal worth up to $2.65 billion, including $1.55 billion upfront and up to $1.1 billion in milestone payments.

Road Ahead in 2026

Consolidation remains a key theme as companies seek to offset patent cliffs and diversify revenue streams. Acquisitions offer a faster, less risky route than in-house development, especially as innovation cycles shorten.

With strong cash reserves and increasing adoption of advanced technologies like AI, M&A activity is expected to remain robust through 2026. Smaller biotechs, often constrained by funding, will likely remain prime acquisition targets, further fueling deal momentum.

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report

Novartis AG (NVS) : Free Stock Analysis Report

Merck & Co., Inc. (MRK) : Free Stock Analysis Report

Eli Lilly and Company (LLY) : Free Stock Analysis Report

Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

For Immediate Release

Chicago, IL – June 11, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Merck & Co., Inc. MRK, The Southern Co. SO, Lumentum Holdings Inc. LITE and Peoples Bancorp of North Carolina, Inc. PEBK.

Here are highlights from Wednesday’s Analyst Blog:

Top Research Reports for Merck, Southern Company and Lumentum

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc., The Southern Co. and Lumentum Holdings Inc., as well as a micro-cap stock Peoples Bancorp of North Carolina, Inc.. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.

These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today's research reports here >>>

Today's Featured Research Reports

Merck's shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+53.3% vs. +25.2%). The company's blockbuster drug, Keytruda, and new products have been driving sales. Animal Health is also contributing to growth. Though Keytruda will lose patent exclusivity in 2028, its sales are expected to remain strong until then.

Merck's new products, Winrevair, Welireg and Capvaxive, key pipeline progress and expansion of its respiratory and infectious disease and oncology portfolios through the acquisitions of Verona Pharma, Cidara Therapeutics and Terns Pharmaceuticals have improved its long-term growth prospects. This progress has increased confidence that Merck can maintain growth even after Keytruda loses exclusivity.

However, it faces several near-term challenges, including persistent challenges for Gardasil in China, potential competition for Keytruda, and rising competitive and generic pressure on some of its drugs.

(You can read the full research report on Merck here >>>)

Shares of Southern Company have gained +7.1% over the past year against the Zacks Utility - Electric Power industry's gain of +23.2%. The company is a leading U.S. electric utility with a stable, recession-resistant business model, benefiting from strong electricity demand growth, particularly from data centers and hyperscale customers, and a robust pipeline exceeding 75 gigawatts of potential projects.

Southern Company is expanding its regulated generation and transmission assets, investing in battery storage and renewable projects, and maintaining a 25-year streak of dividend increases, appealing to income-focused investors.

However, elevated leverage with $67.1 billion in long-term debt, capital-intensive infrastructure needs, exposure to economic slowdowns, regulatory risks, ongoing depreciation charges, and weather-driven earnings volatility limit financial flexibility. Hence, investors are advised to wait for a better entry point.

(You can read the full research report on Southern Company here >>>)

Lumentum's shares have outperformed the Zacks Communication - Components industry over the past year (+968.3% vs. +313.6%). The company is benefiting from sustained AI and cloud network buildouts, with record fiscal Q3 revenue and expanding profitability as laser chips and cloud transceivers scale.

Management's Q4 outlook calls for another step up in revenue and operating margin, supported by continued EML growth, scale-across components like pump and narrow linewidth lasers, and a ramp in 1.6T transceivers with initial internal CW laser integration. A multiyear OCS purchase agreement and the acquisition of an additional indium phosphide fab, backed by a larger cash balance, extend capacity and visibility, while CPO development moves toward revenue.

However, supply constraints and outsourcing dependence can delay shipments, and ongoing ASP and customer concentration risks remain a headwind. Industrial lasers remain muted and can dilute the mix.

(You can read the full research report on Lumentum here >>>)

Shares of Peoples Bancorp of North Carolina have outperformed the Zacks Banks - Southeast industry over the past year (+66.1% vs. +15.4%). This microcap company with a market capitalization of $236.97 million has its investment thesis supported by improving earnings power, driven by balance-sheet management, loan growth and a stable deposit franchise. Margin expansion reflects effective asset-liability management and favorable funding dynamics, while loan growth continues to support revenue generation.

Strong capital levels and a conservative dividend policy provide flexibility to support future growth and shareholder returns. However, key risks include rising operating expenses, potential margin compression from higher funding costs and higher credit costs tied to portfolio growth.

Fee income remains sensitive to appraisal-related activity. Valuation reflects investor caution around the sustainability of earnings growth and credit performance. Further upside will depend on sustaining profitability, maintaining credit quality and delivering consistent earnings growth.

(You can read the full research report on Peoples Bancorp of North Carolina here >>>)

Story Continues

Free: Instant Access to Zacks' Market-Crushing Strategies

Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.

Today you can tap into those powerful strategies – and the high-potential stocks they uncover – free. No strings attached.

Get all the details here >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Southern Company (The) (SO) : Free Stock Analysis Report

Merck & Co., Inc. (MRK) : Free Stock Analysis Report

Lumentum Holdings Inc. (LITE) : Free Stock Analysis Report

Peoples Bancorp of North Carolina, Inc. (PEBK) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Investors deciding between Lexicon Pharmaceuticals(NASDAQ:LXRX) and Pfizer(NYSE:PFE) face a choice between an emerging high-growth biotech player and an established global pharmaceutical titan with massive scale.

These two companies operate at opposite ends of the size spectrum, with one focusing on specialized precision medicine while the other manages a vast portfolio of vaccines and therapies. This comparison explores their recent financial health and risk profiles.

The case for Lexicon Pharmaceuticals

Lexicon Pharmaceuticals operates as a contender among biotech stocks by utilizing gene science to develop treatments for chronic conditions. The company primarily focuses on its commercial product, INPEFA, while licensing its programs to partners like Viatris for international markets. Specific customer concentration data was not disclosed in recent filings.

In FY 2025, revenue reached nearly $49.8 million, representing approximately 60% growth over the previous year. Despite this improvement, the company reported a net loss of $50.3 million for the period.

As of its December 2025 balance sheet, the debt-to-equity ratio was roughly 0.6x. This ratio compares total debt to shareholder equity, indicating the extent to which a firm relies on borrowed money.

The case for Pfizer

Pfizer is a global biopharmaceutical leader that discovers, manufactures, and distributes medicines and vaccines across approximately 200 countries. With a workforce of nearly 75,000 employees, the company maintains a dominant presence in both developed and emerging markets. Its scale allows it to manage a massive product pipeline simultaneously, though specific major customers are not disclosed in its filings.

During FY 2025, revenue reached approximately $62.6 billion, representing a slight decrease of nearly 1.6% from the prior year. The company reported net income of roughly $7.8 billion. This level of profitability resulted in a net margin of close to 12.4%.

Based on the December 2025 balance sheet, the debt-to-equity ratio was approximately 0.8x. Free cash flow for the fiscal year was approximately $9.1 billion, providing substantial capital for dividends and research.

Risk profile comparison

Lexicon Pharmaceuticals faces significant regulatory risks, particularly regarding the approval process for candidates such as ZYNQUISTA for type 1 diabetes. The company also carries an accumulated deficit of nearly $2.0 billion, which may necessitate additional capital raises on unfavorable terms. Furthermore, a single entity, Artal Group, holds roughly 35% of the shares, limiting the influence of smaller retail shareholders.

Story Continues

Pfizer faces significant revenue concentration, with 12 products accounting for roughly 65% of its total 2025 revenue. The company faces a period of patent expirations between 2026 and 2030, which could lead to significant competition from generic drug makers. Additionally, government pricing regulations and competition from large peers such as Eli Lilly (NYSE:LLY) and Merck (NYSE:MRK) could affect long-term profitability.

Valuation comparison

While Lexicon Pharmaceuticals lacks a Forward P/E due to its net losses, Pfizer appears much more affordable based on its P/S ratio.

Metric Lexicon Pharmaceuticals Pfizer Sector Benchmark Forward P/E n/a 8.7x 24.9x P/S ratio 16.8x 2.3x

Sector benchmark uses the SPDR XLV sector ETF. Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.

Which stock would I buy in 2026?

Finding a low-priced, development-stage biotech stock that explodes into a long-term 10-bagger on the success of a treatment that eventually reaches market is a dream for investors. Unfortunately, it usually stays that way: a dream that doesn’t become reality. Development-stage pharma companies often fail to get a blockbuster drug to market.

Lexicon Pharmaceuticals is not exactly development stage. It has one product on the market, INPEFA, for a once-a-day tablet for treating heart failure, but it generated just $1.1 million in sales in the first quarter of 2026. Most of the interest around Lexicon is for developmental drugs for chronic pain and cardiometabolic treatments. There are some positives in the trials, but it’s always worth keeping in mind that positive trials can still fail to bring a drug to market due to late regulatory rejections or a developer’s belief that the drug won’t find much market. Lexicon’s low stock price, which has traded between $1 and $2.50 since July 2025, indicates the speculative nature of the business.

Pfizer isn’t a hot growth stock, but it’s also one of the giants of the pharmaceutical industry. The company had a post-COVID letdown of sorts, as pandemic-related demand ebbed, but the business has been flexing its might this year. In its first quarter, Pfizer beat Wall Street analysts’ expectations on sales and net income. That is partly because Pfizer has been buying growth — it recently acquired oncology specialist Seagen and posted 20% growth in that business’s products. Prifzer is also allocating significant resources to new drug development, with 20 drug development starts scheduled for 2026 and eight data readouts expected, which report on the progress of treatments in development. After falling behind in the GLP-1 weight-loss drug market, Pfizer is also making strides toward becoming a competitor, with very positive Phase II (of III) trial results for an injectable GLP-1 reported earlier this year.

With more than $6 billion in cash, a forward price-to-earnings ratio of a bargain basement 8.7, and a tasty yield of 7% based on its recent price of $26, Pfizer is the choice for 2026.

Should you buy stock in Lexicon Pharmaceuticals right now?

Before you buy stock inLexicon Pharmaceuticals, consider this:

The Motley FoolStock Advisoranalyst team just identified what they believe are the 10 best stocksfor investors to buy now… andLexicon Pharmaceuticalswasn’t one of them. The 10 stocks that made the cut are built for long-term growth and could produce monster returns in the coming years.

Consider whenNetflixmade this list on December 17, 2004... if you invested $1,000 at the time of our recommendation,you’d have $442,220! Or when Nvidiamade this list on April 15, 2005... if you invested $1,000 at the time of our recommendation,you’d have $1,230,114!

That performance is why people listen. With a track record ofbeating the S&P 500 by nearly 5x,Stock Advisoroffers a distinct advantage. Don't miss the latest top 10 list, available withStock Advisor, and join an investing community built for the long haul.

See the 10 stocks »

*Stock Advisor returns as of June 11, 2026.

Brendan Coffey has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly, Merck, and Pfizer. The Motley Fool has a disclosure policy.

Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026? was originally published by The Motley Fool

View Comments